Clinically reviewed by Dr. Sarah Boss, MD
Slow or absent breathing, collapse or inability to wake someone is an emergency. Use available naloxone according to its instructions and call local emergency services. Do not attempt an unsupervised opioid detox or stop ongoing treatment because of a general warning about interactions.
Medication for opioid use disorder is treatment, not simply a temporary bridge to being medication-free. Buprenorphine, methadone and naltrexone have different mechanisms, starting requirements and practical demands. Naloxone has a separate emergency role. Understanding these distinctions helps prevent a common mistake: treating the end of withdrawal as the end of care. The right plan should support safety, daily functioning and continuing treatment for both addiction and other health needs.
What is being treated?
Opioid use disorder involves a problematic pattern of opioid use and its consequences. Physical dependence and tolerance can also develop during prescribed pain treatment, so they should not be used alone to label someone as having an addiction. Assessment considers control over use, continued use despite harm, the impact on life and the wider clinical history. Prescription pain medicines and nonprescribed opioids both belong in that discussion.
Describe the actual substance or product, timing, route, other medicines, previous overdoses and what happens when use is interrupted. The clinician also needs to assess pain, pregnancy, physical illness, mental health and immediate safety. A useful plan should address the problem identified rather than assume every person with withdrawal needs the same treatment setting.
Why ongoing medication matters
CDC identifies buprenorphine, methadone and naltrexone as medications for opioid use disorder. Medication treatment is associated with lower overdose and overall mortality risk. It specifically advises against detoxification alone without ongoing medication treatment for opioid use disorder because returning to use after loss of tolerance creates serious risk. [1]
This does not mean every medicine suits every patient or that treatment has a fixed duration. It means that a plan should look beyond getting through the first uncomfortable days. Ask what will address cravings, reduce risk, maintain access to care and support life after a hospital or residential stay. An arbitrary deadline for becoming medication-free is not an adequate measure of recovery.
Buprenorphine and buprenorphine with naloxone
Buprenorphine is a partial opioid agonist that can suppress withdrawal and reduce cravings. Products used for opioid use disorder include preparations dissolved in the mouth and certain longer-acting injections, depending on the jurisdiction. Other buprenorphine preparations are intended for pain and should not be treated as automatic substitutes. [2]
Buprenorphine-naloxone combines the treatment medicine with an antagonist to discourage certain forms of misuse. The naloxone contained in the combination is not an emergency rescue dose and does not guarantee protection from overdose. A person taking the combination may still need separately supplied naloxone and training in how to use it.
Starting buprenorphine requires a product-specific clinical plan because it can precipitate withdrawal in someone who still has other opioids occupying receptors. The timing is not safely determined by a universal number of hours, particularly when the substances used are uncertain. Do not copy another person’s induction instructions or try to manage a severe reaction with extra medicines.
Methadone and the need for careful initiation
Methadone is a full opioid agonist used to reduce withdrawal and cravings. It can support long-term treatment, but its accumulation, respiratory effects and interactions make initiation and dose changes important clinical decisions. A person should not take extra methadone because the immediate effect seems less noticeable than expected. [3]
Heart-rhythm risks and other medicines may influence monitoring. The arrangements for prescribing, dispensing and take-home doses vary by country and service. In the US, methadone for opioid use disorder is generally provided through regulated opioid treatment programs, with limited exceptions; this framework should not be presented as the rule in every country. [4]
After missed doses, illness or a period away from treatment, contact the service before returning to the previous routine. Tolerance and the clinical situation may have changed. Tell other healthcare teams about methadone before surgery, pain treatment or a new prescription so they can coordinate care rather than making assumptions about the medicine’s purpose.
Naltrexone has a different starting requirement
Naltrexone blocks opioid receptors rather than acting as an opioid agonist. Oral tablets and a longer-acting injection have different adherence demands, evidence and approved wording. SAMHSA’s treatment guidance distinguishes the historical oral approval for opioid blockade from extended-release injectable treatment for prevention of return to opioid dependence following withdrawal. [5]
Naltrexone can precipitate severe withdrawal if started while someone is physically dependent on opioids. The prescriber must assess recent exposure, the opioid involved and the relevant product requirements. A negative test or a remembered date is not a substitute for the full assessment. It also complicates opioid pain treatment, so planned procedures and emergency care need clear communication.
Trying to overcome the blockade with large amounts of an opioid is dangerous. Risk can also increase when protection wanes or treatment stops because tolerance may be reduced. Naltrexone does not remove the need for overdose-prevention education, access to rescue medication and a continuing-care plan.
Withdrawal medicines are not all maintenance treatments
Lofexidine and selected use of clonidine may address some withdrawal symptoms under clinical supervision. They do not have the same role as ongoing treatment with buprenorphine or methadone, and relief of sweating or restlessness does not establish that overdose risk and cravings have been adequately addressed.
Similarly, a medicine used for nausea or sleep is not treatment for the whole disorder. Before withdrawal management begins, ask what happens afterward, which service will continue treatment and how the person will obtain the next prescription. The existing opioid withdrawal guide explains why the transition into continuing treatment matters.
Naloxone and emergency response
Naloxone reverses opioid overdose; it is not a daily maintenance medicine for opioid use disorder. Slow or absent breathing, inability to wake someone or collapse requires immediate action. Use available naloxone according to the product instructions, call local emergency services and follow their guidance about breathing support and further doses. Stay with the person until help arrives. [6]
Improvement after naloxone does not remove the need for emergency assessment. Its effects can wear off while an opioid remains active. Household members and other trusted supporters should know where the rescue medicine is kept and how to use the actual device. Emergency planning should be practical, not dependent on remembering a complex medical explanation under stress.
Alcohol, benzodiazepines and other interactions
Combining opioids with alcohol, benzodiazepines or other sedating medicines can increase the risk of respiratory depression. The treating team needs the complete list, including nonprescribed use. Do not hide a sedative prescription from an addiction service or an opioid-treatment prescription from a mental health clinician.
The interaction risk does not justify automatically withholding buprenorphine or methadone solely because benzodiazepines are involved. FDA has warned that untreated opioid addiction can cause greater harm and recommends careful medication management. This calls for coordination and individualized risk reduction, not independently stopping either medicine or assuming the combination is safe. [7]
Physical health and dental care
Discuss liver disease, breathing problems, cardiac history, infections, pregnancy and current pain. Monitoring depends on the medicine and the person’s circumstances. Significant sedation, new confusion, a seizure or chest symptoms needs assessment. A new physical complaint should not be dismissed as an inevitable feature of addiction or withdrawal.
Buprenorphine preparations dissolved in the mouth have a specific warning about dental problems. FDA emphasizes that treatment benefits outweigh this risk and that patients should not suddenly stop. Dental assessment and the product’s recommended oral-care steps should be part of continuing care, particularly when treatment will be prolonged. This warning should not be generalized to every formulation. [8]
Mental health, pregnancy and coordinated support
Depression, anxiety, trauma symptoms or another psychiatric condition may coexist with opioid use disorder. Some symptoms change with intoxication, withdrawal or stabilization; others need their own ongoing treatment. Assessment should consider timing without requiring a person to ignore severe distress until they have achieved a particular period of abstinence.
Pregnancy requires prompt specialist coordination. Methadone and buprenorphine can have important roles in treatment during pregnancy; abrupt self-directed withdrawal is not the appropriate response to fear about fetal exposure. The team should coordinate addiction treatment, maternity care, other prescriptions and the plan after birth. Advice about one product should not be transferred casually to another. [3]
Psychological support and continuity after discharge
Offer psychological, social and practical support according to need, but lack of access to counseling or a decision not to participate should not delay medication for opioid use disorder. CDC explicitly makes this distinction. Housing, transport, pain care, relationships and employment can all affect whether a plan is workable. [1]
Before discharge or a move between services, confirm the next appointment, medicine supply, dispensing arrangements, naloxone access and contact for missed doses. Do not rely on a general instruction to find a prescriber later. A named handover reduces uncertainty at a time when a treatment gap can have serious consequences.
Frequently asked questions
Is taking methadone or buprenorphine a failure to recover?
No. These medicines are evidence-based treatments. The relevant questions concern safety, functioning, reduced harm and the person’s goals, not whether recovery fits someone else’s medication-free ideal.
Which medicine is best?
There is no universal answer. Prior response, current opioid exposure, treatment preferences, physical health, pain needs and practical access all matter. Starting requirements differ and must be assessed individually.
Does detox remove overdose risk?
No. Reduced tolerance can make a return to previous use especially dangerous. A withdrawal plan should lead into ongoing treatment and overdose prevention, not simply end when symptoms settle.
What should I prepare for a review?
Bring the actual medicines and use pattern, missed doses, recent symptoms and the main practical barrier to care. The medication-review checklist can help organize the discussion without delaying urgent help.


